Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.
Christos SachpekidisJ HillengassH GoldschmidtB WagnerU HaberkornK KopkaA Dimitrakopoulou-StraussPublished in: European journal of nuclear medicine and molecular imaging (2016)
F-FDG PET/CT demonstrated a sensitivity of 57.7 % and a specificity of 100 % in treatment response evaluation of MM. Despite its limited sensitivity, the performance of 18F-FDG PET/CT was satisfactory, given that 6/9 false negative patients in follow-up scans (66.7 %) were clinically characterized as nCR, a disease stage with very low tumor mass. On the other hand, 18F-NaF PET/CT does not seem to add significantly to 18F-FDG PET/CT in treatment response evaluation of MM patients undergoing HDT and ASCT, at least shortly after therapy.
Keyphrases
- pet ct
- high dose
- stem cell transplantation
- patients undergoing
- end stage renal disease
- positron emission tomography
- multiple myeloma
- low dose
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- computed tomography
- bone marrow
- prognostic factors
- cell therapy
- magnetic resonance
- squamous cell carcinoma
- locally advanced